Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio
Pfizer is set to enter the heated VEGF bispecific arena.
Much like its peers, the New York drug giant is doing so by going to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
